The Pharma Services business of Thermo Fisher Scientific will invest $150 Million at three facilities.

The Companies Law permits merger transactions if approved by each party’s board of directors, and, unless certain requirements described under the Companies Law are met, a majority of each party’s shareholders, by a majority of each party’s shares that are voted on the proposed merger at a shareholders’ meeting.

If our operations are found to be in violation of any such health care laws and regulations, we may be subject to penalties, including administrative, civil and criminal penalties, monetary damages, disgorgement, imprisonment, the curtailment or restructuring of our operations, loss of eligibility to obtain approvals from the FDA or foreign regulatory authorities, or exclusion from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid, any of which could adversely our financial results. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management’s attention from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may be costly to us in terms of money, time and resources.

Jeffery, T. K. & Morrell, N. W. Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension. Prog. Cardiovasc. Dis. 45, 173–202 (2002).

Jansen, J. H. et al. Stimulation of osteogenic differentiation in human osteoprogenitor cells by pulsed electromagnetic fields: an in vitro study. BMC Musculoskel. Dis. 11, 188 (2010).

        If a product with orphan status receives the first FDA approval for the disease or condition for which it has such designation or for a select indication or use within the rare disease or condition for which it was designated, the product generally will be receiving orphan product exclusivity. Orphan product exclusivity means that the FDA may not approve any other applications for the same product for the same indication for seven years, except in certain limited circumstances. Competitors may receive approval of different products for the indication for which the orphan product has exclusivity and may obtain approval for the same product but for a different indication. If a drug or drug product designated as an orphan product ultimately receives marketing approval for an indication broader than what was designated in its orphan product application, it may not be entitled to exclusivity.

Our policy is to pursue, maintain and defend patent rights, whether developed internally or licensed from third parties, and to protect the technology, inventions and improvements that are commercially important to the development of our business. We also rely on trade secrets that may be important to the development of our business.

As Alan says we’ll have to wait for a safe viral vector and gene therapy to have telomeres extended significantly, but we might not need to wait for FDA approval. Just look at Bioviva’s website. These guys look like they are setting up clinics as we speak, the price will presumably start very high and then come down to more realistic levels.

lease component as a single component. The Company is still evaluating the full impact this standard will have on its consolidated financial statements and related disclosures but expects to recognize substantially all of its leases on the balance sheet by recording a right-to-use asset and a corresponding lease liability. The Company has formalized processes and controls to identify, classify and measure new leases in accordance with ASU 2016-02.

Treatment of CHO-K1 cells expressing human HCN1 channels by MβCD resulted in reduced current density compared to untreated control cells (Fig. 1A,B). To verify that this effect was specific to the effects of membrane cholesterol, and not due to unspecific effects of MβCD, we also examined the effect of 30 μM mevastatin, which blocks cholesterol synthesis. Similar to the effect of MβCD, current densities were also reduced in cells treated with mevastatin. While there was a trend towards an increase in the current density with the enrichment of cellular cholesterol by MβCD/cholesterol (P = 0.12), statistical significance could not be resolved. Both depletion and enrichment had no effect on the steady-state activation properties of HCN1 channels (Fig. 1C; Table 1). HCN1 activation currents can be described by a dual-exponential function, whose fast time component (τfast) was unchanged by modulation of membrane cholesterol (Fig. 1D), however, cholesterol depletion reduced the slow component of activation (τslow) by 2-fold (Fig. 1E). No observable effect on HCN1 deactivation kinetics could be discerned.

Well Aldebaran it’s hard to argue with your very logical mathematical mind. I like option 1. Being 105 in good health is good stuff. I’ll take it.

To date, our independent public accountant has never conducted a review of our internal control for the purpose of providing the reports required by these rules. During the course of our review and testing, we may identify deficiencies and be unable to remediate them before we must provide the required reports. Furthermore, if we have a material weakness in our internal controls over financial reporting, we may not detect errors on a timely basis and our financial statements may be materially misstated. We or our independent registered public accounting firm may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting, which could harm our operating results, cause investors to lose confidence in our reported financial information and cause the trading price of our stock to fall.